MedTrace Logo

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

NCT06077773 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2025-12-19

Study results available
· View outcomes & findings →

Summary

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria

Conditions

Interventions

DRUG

Oral EP262

Once daily

DRUG

Placebo

Once daily

Sponsors & Collaborators

  • Escient Pharmaceuticals, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-25
Primary Completion
2024-12-18
Completion
2025-01-16
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Netherlands
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06077773 on ClinicalTrials.gov